ArticleChemistry & biodiversity2026
d-Alanine Hydrochloride and d-Alanine Dipeptide Have Biological Activity and Promote Human Proximal Tubular Epithelial Cell Viability.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Acute kidney injury (AKI) remains a significant clinical challenge with limited therapeutic options. While d-alanine shows promise in AKI treatment, its formulation requires l-alanine co-inclusion for pharmaceutical stabilization through racemization. This study investigated the biological activity of synthetic d-alanine compounds in the human proximal tubular epithelial cell line (HK-2). We synthesized d-alanine hydrochloride, a dipeptide, and a tripeptide and evaluated their effects on cell viability under normal and hypoxic conditions. d-Alanine hydrochloride (10 µM) and dipeptide (10 µM) significantly enhanced cell viability compared with the controls, with d-alanine hydrochloride demonstrating superior efficacy under hypoxic conditions. Gene expression analysis revealed that these compounds promoted cell cycle progression and increased cyclin B1 expression under hypoxic conditions. Notably, these synthetic forms maintained therapeutic efficacy without requiring l-alanine co-inclusion. Although limited to in vitro experiments, our findings suggest that d-alanine hydrochloride and dipeptide forms are promising therapeutic candidates for AKI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.